Sugi Predict

Sugi Predict / Compounds / SCHEMBL1770481

SCHEMBL1770481

SCHEMBL1770481

CCOC(=O)N1CCN(Cc2ccn(Cc3ccccc3F)c(=O)c2O)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 12/20 0.73
▸ KDM4E B2RXH2 8/20 0.73
▸ POLB P06746 1/20 0.73
▸ VEGFA P15692 3/20 0.53
▸ EGLN1 Q9GZT9 3/20 0.53
▸ TDP1 Q9NUW8 2/20 0.51
▸ ALOX15 P16050 1/20 0.51
▸ LMNA P02545 3/20 0.47
▸ HTT P42858 1/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ KMT2A Q03164 4/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 2/20 0.45
▸ MPI P34949 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ GAA P10253 2/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17005878 0.92 ALDH1A1 (0.61) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL1770324 0.91 KDM4E (0.58) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL17005901 0.90 ALDH1A1 (0.68) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL17005891 0.90 ALDH1A1 (0.57) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL1770721 0.88 VEGFA (0.69) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL17005974 0.88 ALDH1A1 (0.59) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL17005983 0.88 ALDH1A1 (0.70) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL17005936 0.88 KDM4E (0.55) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL17005876 0.88 KDM4E (0.55) ALDH1A1KDM4EPOLBVEGFAEGLN1
SCHEMBL1770528 0.88 ALDH1A1 (0.73) ALDH1A1KDM4EPOLBVEGFAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2853265-B1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC (US) 2017-07-26 — — EP claimed
EP-2496084-B1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS INC (US) 2015-06-10 — — EP claimed
US-9045495-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC. (US) 2015-06-02 — — US claimed
EP-2853265-A1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha Aerpio Therapeutics Inc. (US) 2015-04-01 — — EP claimed
EP-2649998-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2015-03-04 — — EP claimed
US-8883774-B2 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC. (US) 2014-11-11 — — US claimed
US-8778412-B2 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC. (US) 2014-07-15 — — US claimed
EP-2649998-A1 Prolyl hydroxylase inhibitors Aerpio Therapeutics Inc. (US) 2013-10-16 — — EP claimed
US-8536181-B2 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC. (US) 2013-09-17 — — US claimed
US-20130158010-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS INC. (US) 2013-06-20 — — US claimed
US-20130158045-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC. (US) 2013-06-20 — — US claimed
EP-2496236-B1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2013-05-01 — — EP claimed
US-8309537-B2 Compositions and methods for treating colitis AERPIO THERAPEUTICS INC. (US) 2012-11-13 — — US claimed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US claimed
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS LLC 2011-05-12 — — US claimed
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 — — US disclosed
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS AERPIO THERAPEUTICS INC (US) 2022-06-16 — — US disclosed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed
WO-2011057121-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AKEBIA THERAPEUTICS INC. (US) 2011-05-12 — — WO disclosed
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS AERPIO THERAPEUTICS LLC 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112055-A1 COMPOSITIONS AND METHODS FOR TREATING COLITIS ALPI, SI, SLC10A2 ALDH1A1 780/4885KDM4E 4207/4885POLB 1579/4885
US-20130158045-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 652/4885KDM4E 249/4885POLB 2712/4885
US-20220185778-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 652/4885KDM4E 249/4885POLB 2712/4885
US-20130158010-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA HIF1A, HIF1AN, EGLN3 ALDH1A1 505/4885KDM4E 2523/4885POLB 1226/4885
US-20110110961-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, HIF1A, EGLN2 ALDH1A1 652/4885KDM4E 249/4885POLB 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.